Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 evaluation of daclatasvir/asunaprevir/BMS-791325 fixed-dose combination in non-cirrhotic genotype 1 chronic hepatitis C
2013-002468-20Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of daclatasvir, asunaprevir and beclabuvir in hepatitis C virus infection, sponsored by Bristol Myers Squibb. Primary endpoint: SVR12 in treatment-naive cohort. Started Jun 2015; status: completed.
02
Drugs
daclatasvirasunaprevirbeclabuvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2013-002468-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002468-20.